These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: MicroRNA-33b inhibits tumor cell growth and is associated with prognosis in colorectal cancer patients.
    Author: Liao W, Gu C, Huang A, Yao J, Sun R.
    Journal: Clin Transl Oncol; 2016 May; 18(5):449-56. PubMed ID: 26329295.
    Abstract:
    PURPOSE: To explore the role of miR-33b in colorectal cancer (CRC) and the correlation between its expression and prognosis. METHODS: The expressions of miR-33b between CRC tissues and normal tissues were measured by real-time PCR. The effects of miR-33b on cell proliferation and cell cycle progression were detected by MTT assay, colony formation assay and flow cytometry. The potential regulations of miR-33b on multiple genes expression were verified by Western blot. Furthermore, the association of miR-33b with CRC clinicopathologic features and prognosis was analyzed by Chi-squared test and Kaplan-Meier tests. RESULTS: MiR-33b was downregulated in CRC compared with normal colorectal samples and miR-33b inhibited tumor cell growth and induced cell cycle arrest. Western blot assays and correlation analysis showed that miR-33b could regulate multiple growth-related genes. Moreover, the expression of miR-33b was associated with TNM stage and tumor size, and CRC patients with high miR-33b expression had a better prognosis. CONCLUSION: Our data suggest that miR-33b functions as a tumor suppressor gene in CRC through regulating cell proliferation and cell cycle.
    [Abstract] [Full Text] [Related] [New Search]